The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of prostate cancer drug Xofigo...
Read More...
The post EMA’s safety committee advises limiting use of Xofigo appeared first on Pharmaceutical Technology.
Original Article: EMA’s safety committee advises limiting use of Xofigo